The goal of this observational study is to learn about the real-world effectiveness of Guishen Yijing Formula in women with diminished ovarian reserve (DOR). The main question it aims to answer is: Does Guishen Yijing Formula improve ovarian reserve function in women with DOR after 3 months of treatment? Medical records of participants who received Guishen Yijing Formula as part of their routine clinical care for DOR will be reviewed. Changes in anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), and symptom scores before and after treatment will be analyzed.
Study Type
OBSERVATIONAL
Enrollment
126
Dongzhimen Hospital, Beijing University of Chinese Medicine
Beijing, China
Change in Serum Anti-Müllerian Hormone (AMH) Level
Change in serum AMH level before and after 3 months of treatment, measured by blood test.
Time frame: From baseline to 3 months after treatment initiation
Serum Follicle-Stimulating Hormone (FSH)
Blood samples are collected before and after treatment.
Time frame: From baseline to 3 months after treatment initiation
Serum Luteinizing Hormone (LH)
Blood samples are collected before and after treatment.
Time frame: From baseline to 3 months after treatment initiation
FSH/LH Ratio
Change in FSH/LH ratio before and after treatment.
Time frame: From baseline to 3 months after treatment initiation
Serum Estradiol (E2)
Blood samples are collected before and after treatment.
Time frame: From baseline to 3 months after treatment initiation
Traditional Chinese Medicine Syndrome Score
This syndrome score evaluates three primary symptoms and ten secondary symptoms related to traditional Chinese medicine syndrome differentiation. Total scores range from 0 to 48, with higher scores indicating more severe syndrome manifestations and a worse clinical outcome.
Time frame: before and 1 month after the treatment
Modified Kupperman Menopausal Index (KMI)
The modified KMI consists of 13 menopausal symptoms, each rated on a 0-3 severity scale and weighted by symptom-specific coefficients. Total scores range from 0 to 63, with higher scores indicating more severe menopausal symptoms and a worse clinical outcome.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: before and 1 month after the treatment
Incidence of Treatment-Emergent Adverse Events
The incidence of treatment-emergent adverse events during the treatment period will be assessed, including gastrointestinal symptoms and abnormalities in liver and renal function.
Time frame: From baseline to 3 months after treatment initiation